Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1636 1637 1699
This examiner grants 54% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17602076 | Enhancement of Melanocyte Migration Using ROCK Inhibitors | Non-Final OA | The General Hospital Corporation |
| 18275634 | Methods of Protecting RNA | Non-Final OA | Pfizer Inc. |
| 17438920 | MODIFYING THE SPECIFICITY OF NON-CODING RNA MOLECULES FOR SILENCING GENES IN EUKARYOTIC CELLS | Final Rejection | Tropic Biosciences UK Limited |
| 17635363 | COMBINATION THERAPY FOR SPINAL MUSCULAR ATROPHY | Non-Final OA | Biogen MA Inc. |
| 17291922 | An lncRNA integrates a DNA-PK-mediated DNA damage response and vascular senescence | Non-Final OA | The Brigham and Women`s Hospital, Inc. |
| 18272699 | SEQUENTIAL DELIVERY OF RNPS TO IMMUNE CELLS | Non-Final OA | Avectas Limited |
| 17299275 | METHODS FOR THE TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS ASSOCIATED WITH OGG1 ACTIVITY | Non-Final OA | TAKEDA PHARMACEUTICALS U.S.A., INC. |
| 17997138 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR AT LEAST ONE TYPE OF CANCER SELECTED FROM GROUP CONSISTING OF PANCREATIC CANCER, LUNG CANCER, COLORECTAL CANCER, CHOLANGIOCARCINOMA AND LIVER CANCER, PROPHYLACTIC OR THERAPEUTIC AGENT FOR SAID CANCER WHICH IS USED IN COMBINATION DRUG IN COMBINATION WITH SAID AGENT, COMBINATION DRUG COMPRISING SAID AGENTS, AND METHOD FOR SCREENING FOR PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER | Non-Final OA | TAK-CIRCULATOR CO., LTD. |
| 17915215 | Targeted Inhibition Using Engineered Oligonucleotides | Non-Final OA | miRecule, Inc. |
| 17287563 | METHOD FOR SUPPRESSING PROTEIN TRANSLATION REACTION USING STAPLE NUCLEIC ACID | Non-Final OA | HIROSAKI UNIVERSITY |
| 17216169 | Adult Stem Cell Line Introduced with Hepatocyte Growth Factor Gene and Neurogenic Transcription Factor Gene with Basic Helix-Loop-Helix Motif and Uses Thereof | Non-Final OA | CELL&BRAIN CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy